DOCSLIB.ORG

CRASH Syndrome: Clinical Spectrum Vance Lemmon0 Guy Van Campa of Corpus Callosum Hypoplasia, Lieve Vitsa Retardation, Adducted Thumbs, Paul Couckea Patrick J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CRASH Syndrome: Clinical Spectrum Vance Lemmon0 Guy Van Campa of Corpus Callosum Hypoplasia, Lieve Vitsa Retardation, Adducted Thumbs, Paul Couckea Patrick J Review 1608178 Eur J Hum Genet 1995;3:273-284 Erik Fransen3' CRASH Syndrome: Clinical Spectrum Vance Lemmon0 Guy Van Campa of Corpus Callosum Hypoplasia, Lieve Vitsa Retardation, Adducted Thumbs, Paul Couckea Patrick J. Willemsa Spastic Paraparesis and a Department of Medical Genetics, Hydrocephalus Due to Mutations in University of Antwerp, Belgium; One Single Gene, L1 b Case Western Reserve University, Cleveland, Ohio, USA Keywords Abstract X-linked disorder LI is a neuronal cell adhesion molecule with important func­ Mental retardation tions in the development of the nervous system. The gene Hydrocephalus encoding LI is located near the telomere of the long arm of the MASA syndrome X chromosome in Xq28. We review here the evidence that Adducted thumbs several X-linked mental retardation syndromes including X- Corpus callosum agenesis linked hydrocephalus (HSAS), MASA syndrome, X-linked Spastic paraplegia complicated spastic paraparesis (SPI) and X-linked corpus LI callosum agenesis (ACC) are all due to mutations in the LI CRASH gene. The inter- and intrafamilial variability in families with Mutation analysis an LI mutation is very wide, and patients with HSAS, MASA, SPI and ACC can be present within the same family. There­ fore, we propose here to refer to this clinical syndrome with the acronym CRASH, for Corpus callosum hypoplasia, Retar­ dation, Adducted thumbs, Spastic paraplegia and Hydroceph­ alus. Clinical Aspects for Hydrocephalus due to Stenosis of the Aqueduct of Sylvius. This designation was X-Linked Hydrocephalus based upon the presence of aqueductal steno­ X-linked hydrocephalus (MIM No. sis in many HSAS patients [1]. However, later 307000) was originally described by Bickers studies reported several HSAS patients with and Adams in 1949. It is referred to as HSAS hydrocephalus but without aqueductal steno- Received: April 21,1995 Patrick Willems © 1995 Revision received: July 28,1995 Department of Medical Genetics S. Karger AG, Basel Accepted: August 4, 1995 University of Antwerp B-2610 Antwerp (Belgium) sis [2]. Therefore, the occurrence of aqueduc- reported, and some families have been rede­ tal stenosis in X-linked hydrocephalus might fined as representative of the MASA syn­ not be the cause of hydrocephalus. Neverthe­ drome [9-17], The clinical features show in­ less, the designation of HSAS is still used in ter- and intrafamilial variation, with mental the literature. HSAS is the most common retardation being the only obligatory symp­ genetic cause of hydrocephalus with an inci­ tom. Although MASA syndrome is an X- dence of approximately 1/30,000 male births, linked recessive condition, some expressing and it is responsible for about one quarter of carrier females have been reported, possibly male patients with hydrocephalus not associ­ due to unfavorable lyonization of the wild- ated with spina bifida [3]. The clinical spec­ type gene [9,14], Corpus callosum agenesis or trum of HSAS is very broad and shows great dysgenesis is also a frequent symptom in intra- and interfamilial variation. The only MASA patients [15]. Even though earlier obligate feature is mental retardation, with studies [9] noticed the clinical overlap be­ IQs usually ranging between 20 and 50. Hy­ tween MASA and HSAS, a clear distinction drocephalus presents from impressive macro- was made between those two conditions, cephaly, resulting in pre- or perinatal death, to based upon the presence or absence of hydro­ minimal enlargement of the ventricles. More­ cephalus in HSAS and MASA, respectively. over, HSAS families have been described in However, in later clinical studies, the sharp which some mentally retarded members did boundaries between HSAS and MASA be­ not have hydrocephalus [4, 5]. Adducted gan to fade away as (1) HSAS families were thumbs are seen in approximately 90% of the reported in which some affected members cases. Other features are spastic paraplegia, did not have hydrocephalus [4, 5], (2) some nystagmus and structural brain defects such MASA families contained HSAS patients as hypoplasia of the corpus callosum and sep­ with hydrocephalus [16], and (3) linkage stud­ tum pellucidum [5], HSAS is a recessive X- ies assigned the MASA disease locus to Xq28, linked disorder with no symptoms in carrier the same region as HSAS [16, 17]. This led us females. In 1990, we assigned the HSAS dis­ to suggest that HSAS and MASA were allelic ease locus to the distal part of the long arm of disorders due to mutations in the same gene the X chromosome in Xq28 by linkage analy­ [6]. sis [6], Further mapping studies refined the disease locus to a region of 2 Mb, distal to Spastic Paraplegia DXS52 and proximal to F8C [7, 8]. As the Spastic Paraplegia (SP) is a clinically and neural cell adhesion molecule LI (LICAM) is genetically heterogeneous condition. Some in­ located in this interval, we suggested that vestigators divide SP into pure and compli­ HSAS might be due to mutations in LI [7], cated forms [18], In pure SP, spasticity of the lower extremities is the only clinical sign. In MASA Syndrome complicated SP, additional symptoms such as In 1974, Bianchine and Lewis described an mental retardation and/or congenital brain X-linked disorder characterized by Mental re­ malformations are present. Most hereditary tardation, aphasia, .Shuffling gait and Ad­ forms of SP are inherited in an autosomal ducted thumbs [9], Referring to these four dominant or recessive way, whereas X-linked clinical features, the name ‘MASA syndrome’ SP is rare. A locus for X-linked SP (SP2) has was assigned to this disease (MIM No. been localized on the long arm of the X chro­ 303350). Several MASA families have been mosome in Xq21-q22, both in families with 274 Fransen/Lemmon/V an Camp/Vits/ CRASH Syndrome Coucke/WiUems pure [19] and complicated [20] SP. This lat­ linked recessive condition with ACC and a ter form of SP results from mutations in the variety of symptoms including macrocephaly, proteolipid protein (PLP) gene and is allelic anal anomalies, Hirschsprung’s disease, con­ to Pelizaeus-Merzbacher disease (MIM No. stipation, hypotonia and mental retardation 312080), a severe X-linked disorder in which [22], The gene responsible for FG syndrome progressive demyelination of the central ner­ has been mapped to Xql 3 [Briault, pers. com­ vous system occurs [21], Kenwrick et al. [12] mun.]. Several ACC/DCC syndromes with have described a form of X-linked compli­ unknown sublocalization on the X chromo­ cated SP (SPI, MIM No. 312900) in a family some have been described. Menkes et al. [23] with SP, mental retardation and adducted have reported a family with X-linked ACC/ thumbs. Linkage analysis assigned the SPI DCC, seizures, mental retardation and disease locus to the distal part of the long arm Hirschsprung’s disease, which might repre­ of the X chromosome in Xq28. Later clinical sent an example of FG syndrome. An X- studies of this SPI family revealed that the linked DCC family with hydrocephalus, mi­ clinical spectrum was compatible with MASA crocephaly, mental retardation and brachy- syndrome [17], suggesting that SPI and dactyly has been reported by Kang et al. [24], MASA syndrome are coallelic. Kaplan [25] reported two males with com­ plete absence of the corpus callosum and Agenesis of the Corpus Callosum severe psychomotor retardation, one of the The corpus callosum is the largest fiber patients having adducted thumbs and slightly tract in the brain, and plays a key role in the enlarged ventricles. This spectrum of anoma­ communication between the two brain hemi­ lies is reminiscent of MASA syndrome. The spheres. Corpus callosum agenesis (ACC) or fact that ACC/DCC in some families might dysgenesis (DCC) is a rather aspecific abnor­ represent MASA, is also corroborated by the mality. Many cases of DCC, and to a lesser finding that ACC or DCC have been reported extent ACC, are found incidentally at necrop­ in patients with MASA syndrome [15] and sy in individuals who had normal cerebral HSAS [5]. This suggests that there might be function. The frequency of ACC/DCC in the just one gene for HSAS, MASA, SPI and general population has been estimated at 0.3- ACC/DCC. 0.7%, whereas it is found in 2-3% of the men­ tally retarded. In most cases, ACC/DCC is an isolated finding. However, ACC and DCC Molecular Aspects can also occur as part of a syndrome, when accompanied by a number of other malforma­ Identification of LI as the tions. Many chromosomal and monogenic Disease-Causing Gene in HSAS, MASA, disorders have ACC/DCC in their spectrum SPI and ACC/DCC of anomalies. X-linked forms of ACC/DCC, The localization of the HSAS gene in Xq28 however, are very rare. Aicardi syndrome, an in a 2-Mb interval containing the LI X-linked disorder that occurs only in females, (LICAM) gene suggested that LI was a candi­ has a clinical spectrum including ACC, cho­ date gene for HSAS [7], Therefore, extensive rioretinal lacunae, infantile spasms and psy­ mutation analysis was performed in the LI chomotor retardation. The gene involved in gene from a large number of HSAS families. Aicardi syndrome has provisionally been In 1992, the first LI mutation in an HSAS mapped to Xp22. FG syndrome is an X- family was reported by Rosenthal et al. [26]. 275 Table 1. LI mutations in HSAS, MASA, SPI and ACC families No. Mutation Exon Domain Disease Ref­ cDNA level protein level erence 1 321 Del 80 FS 107 frameshift 4 Ig2 HSAS 29 2 G551A R184Q missense 6 Ig2 HSAS 30 3 C630G H210Q missense 6 Ig2 M ASA/ACC 32 4 G791T C264Y missense 7 Ig3 HSAS 28 5 G1354A G452R missense 11 Ig5 HSAS 30 6 C1453T R485STOP nonsense 12 Ig5 HSAS 30 7 G1792A D598N missense 14 Ig6 MASA 32 8 2137 Ins 39 8121ns 13AA insertion intron 17 Fn2 HSAS 26 9 2884 Del G FS 961 frameshift 22 Fn4 HSAS 30 10 3489 Del TG FS 1163 frameshift 26 cytoplasmic SPI 30 11 C3581T S1194L missense 28 cytoplasmic MASA 31 12 3541 Dpi 125 FS 1223 frameshift 28 cytoplasmic HSAS 27 13 Del 3541-end FS1181 frameshift 26-28 cytoplasmic MASA 32 This was a novel mutation in a branch point LI Protein and Function signal of an intron, leading to aberrant splic­ LI, also referred to as LI CAM, is a neuro­ ing.
Load more

Recommended publications
  • Hereditary Spastic Paraparesis: a Review of New Developments
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.69.2.150 on 1 August 2000. Downloaded from 150 J Neurol Neurosurg Psychiatry 2000;69:150–160 REVIEW Hereditary spastic paraparesis: a review of new developments CJ McDermott, K White, K Bushby, PJ Shaw Hereditary spastic paraparesis (HSP) or the reditary spastic paraparesis will no doubt Strümpell-Lorrain syndrome is the name given provide a more useful and relevant classifi- to a heterogeneous group of inherited disorders cation. in which the main clinical feature is progressive lower limb spasticity. Before the advent of Epidemiology molecular genetic studies into these disorders, The prevalence of HSP varies in diVerent several classifications had been proposed, studies. Such variation is probably due to a based on the mode of inheritance, the age of combination of diVering diagnostic criteria, onset of symptoms, and the presence or other- variable epidemiological methodology, and wise of additional clinical features. Families geographical factors. Some studies in which with autosomal dominant, autosomal recessive, similar criteria and methods were employed and X-linked inheritance have been described. found the prevalance of HSP/100 000 to be 2.7 in Molise Italy, 4.3 in Valle d’Aosta Italy, and 10–12 Historical aspects 2.0 in Portugal. These studies employed the In 1880 Strümpell published what is consid- diagnostic criteria suggested by Harding and ered to be the first clear description of HSP.He utilised all health institutions and various reported a family in which two brothers were health care professionals in ascertaining cases aVected by spastic paraplegia. The father was from the specific region.
    [Show full text]
  • MASA Syndrome in Twin Brothers: Case Report of Sixteen-Year Clinical Follow Up
    Paediatr Croat. 2014;58:286-90 PRIKAZ BOLESNIKA / CASE REPORT www.paedcro.com http://dx.doi.org/10.13112/PC.2014.50 MASA syndrome in twin brothers: case report of sixteen-year clinical follow up Matilda Kovač Šižgorić1, Zlatko Sabol1, Filip Sabol2, Tonći Grmoja3, Svjetlana Bela Klancir1, Zdravka Gjergja1, Ljiljana Kipke Sabol1 MASA syndrome (OMIM 303350) is a rare X-linked recessive neurologic disorder, also called CRASH syndrome, spastic paraplegia 1 and Gareis-Mason syndrome. The acronym MASA describes four major signs: Mental retardation, Aphasia, Shuffl ing gait and Adducted thumbs. A more suitable name for this syndrome is L1 syndrome because the disorder has been associated with mutations in the neuronal cell adhesion molecule L1 (L1CAM) gene. The syndrome has severe symptoms in males, while females are carriers because only one X chromosome is aff ected. The aim of this report is to show similarities and diff erences in clinical manifestations between twins with the L1CAM gene mutation and to emphasize the importance of genetic counseling. Our patients were dizygotic twins born prematurely at 35 weeks of gestation. Pregnancy was complicated with early bleeding and gestational diabetes. Immediately after birth, hypertonia of lower extremities was observed in both twins. Sixteen-year clinical follow up showed spastic paraparetic form with shuffl ing gait, clumsiness, delayed speech development, lower intellectual functioning at the level of mild to moderate mental retarda- tion, primary nocturnal enuresis, behavioral and sleep disorder (more pronounced in the second twin). Magnetic resonance imaging of the brain showed complete agenesis of the corpus callosum, complete lack of the anterior commissure, and internal hydrocephalus.
    [Show full text]
  • GENETIC TESTING REQUISITION Please Ship All
    GENETIC TESTING REQUISITION 1-844-363-4357· [email protected] Schillingallee 68 · 18057 Rostock Germany Attention Patient: Please visit your nearest LifeLabs or CML Healthcare Patient Service Centre for sample collection LL: K012-01/ CML: CEN CONTRACT # Report to Physician Billing # LifeLabs Demographic Ordering Physician Name Label Physician Signature: Ordering Physician Address: Tel: Fax: Address & Contact Info: Copy to (name & contact info): Name: Contact: Bill to Contract # K012-01 (patient does not pay at time of collection) Patient Gender: (M/F) Patient Name (Last, First): Patient DOB: (YYYY/MM/DD) Patient Address: Patient Health Card: Patient Telephone: Please ship all NON-PRENATAL samples to: LifeLabs · Attn CDS Department • 100 International Boulevard• Toronto ON• M9W6J6 TEST REQUESTED LL TR # / CML TC# □ Genetic Test - Blood Sample 2 x 4mL EDTA 4005 □ Genetic Test (Pediatric) - Blood Sample 1 x 2mL EDTA 4008 □ Genetic Test - Other Sample Type 4014 PRENATAL SAMPLES: Please ship directly to CENTOGENE. Date Blood Collected (YYYY/MM/DD): ___________ Time Blood Collected (HH:MM)) :________ Collector Name: ___________________ GENETIC TESTING CONSENT I understand that a DNA specimen will be sent to LifeLabs for genetic testing. My physician has told me about the condition(s) being tested and its genetic basis. I am aware that correct information about the relationships between my family members is important. I agree that my specimen and personal health information may be sent to Centogene AG at their lab in Germany (address below). To ensure accurate testing, I agree that the results of any genetic testing that I have had previously completed by Centogene AG may be shared with LifeLabs.
    [Show full text]
  • Mackenzie's Mission Gene & Condition List
    Mackenzie’s Mission Gene & Condition List What conditions are being screened for in Mackenzie’s Mission? Genetic carrier screening offered through this research study has been carefully developed. It is focused on providing people with information about their chance of having children with a severe genetic condition occurring in childhood. The screening is designed to provide genetic information that is relevant and useful, and to minimise uncertain and unclear information. How the conditions and genes are selected The Mackenzie’s Mission reproductive genetic carrier screen currently includes approximately 1300 genes which are associated with about 750 conditions. The reason there are fewer conditions than genes is that some genetic conditions can be caused by changes in more than one gene. The gene list is reviewed regularly. To select the conditions and genes to be screened, a committee comprised of experts in genetics and screening was established including: clinical geneticists, genetic scientists, a genetic pathologist, genetic counsellors, an ethicist and a parent of a child with a genetic condition. The following criteria were developed and are used to select the genes to be included: • Screening the gene is technically possible using currently available technology • The gene is known to cause a genetic condition • The condition affects people in childhood • The condition has a serious impact on a person’s quality of life and/or is life-limiting o For many of the conditions there is no treatment or the treatment is very burdensome for the child and their family. For some conditions very early diagnosis and treatment can make a difference for the child.
    [Show full text]
  • Psykisk Utviklingshemming Og Forsinket Utvikling
    Psykisk utviklingshemming og forsinket utvikling Genpanel, versjon v03 Tabellen er sortert på gennavn (HGNC gensymbol) Navn på gen er iht. HGNC >x10 Andel av genet som har blitt lest med tilfredstillende kvalitet flere enn 10 ganger under sekvensering x10 er forventet dekning; faktisk dekning vil variere. Gen Gen (HGNC Transkript >10x Fenotype (symbol) ID) AAAS 13666 NM_015665.5 100% Achalasia-addisonianism-alacrimia syndrome OMIM AARS 20 NM_001605.2 100% Charcot-Marie-Tooth disease, axonal, type 2N OMIM Epileptic encephalopathy, early infantile, 29 OMIM AASS 17366 NM_005763.3 100% Hyperlysinemia OMIM Saccharopinuria OMIM ABCB11 42 NM_003742.2 100% Cholestasis, benign recurrent intrahepatic, 2 OMIM Cholestasis, progressive familial intrahepatic 2 OMIM ABCB7 48 NM_004299.5 100% Anemia, sideroblastic, with ataxia OMIM ABCC6 57 NM_001171.5 93% Arterial calcification, generalized, of infancy, 2 OMIM Pseudoxanthoma elasticum OMIM Pseudoxanthoma elasticum, forme fruste OMIM ABCC9 60 NM_005691.3 100% Hypertrichotic osteochondrodysplasia OMIM ABCD1 61 NM_000033.3 77% Adrenoleukodystrophy OMIM Adrenomyeloneuropathy, adult OMIM ABCD4 68 NM_005050.3 100% Methylmalonic aciduria and homocystinuria, cblJ type OMIM ABHD5 21396 NM_016006.4 100% Chanarin-Dorfman syndrome OMIM ACAD9 21497 NM_014049.4 99% Mitochondrial complex I deficiency due to ACAD9 deficiency OMIM ACADM 89 NM_000016.5 100% Acyl-CoA dehydrogenase, medium chain, deficiency of OMIM ACADS 90 NM_000017.3 100% Acyl-CoA dehydrogenase, short-chain, deficiency of OMIM ACADVL 92 NM_000018.3 100% VLCAD
    [Show full text]
  • By Submitted in Partial Satisfaction of the Requirements for Degree of in in the GRADUATE DIVISION of the UNIVERSITY of CALIFORN
    DDX3X and C12ORF57/Camkinin: Insight into the function and malfunction of two genes implicated in agenesis of the corpus callosum by Ruiji Jiang DISSERTATION Submitted in partial satisfaction of the requirements for degree of DOCTOR OF PHILOSOPHY in Biomedical Sciences in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Approved: ______________________________________________________________________________Aimee Kao Chair ______________________________________________________________________________Elliott Sherr ______________________________________________________________________________John Rubenstein ______________________________________________________________________________Kevin Shannon ______________________________________________________________________________ Committee Members ii Acknowledgements I would like to thank Malek Chouchane and Erik Ullian for their assistance in planning and collecting the electrophysiology data for the sections dealing with C12ORF57. The Linda Richards lab at the Queensland Brain Insitute, specifically Ching Moey and also provided valuable support in performing dual stain in situs and immunohistochemistry for the cell type specific expression assays as well as sectioning for mouse brains. Thanks to Suling Wong for her artistic expertise in illustrating our C12ORF57/Camkinin model Stephen Floor and the Doudna lab at Berkeley provided invaluable assistance in explaining the principles of the DDX3X unwinding assay, as well as providing technical assistance in purifying protein,
    [Show full text]
  • Gen- Symbol Genname Erkrankung(En) OMIM Gengröße
    Gen‐ Gengröße Genname Erkrankung(en) OMIM symbol (kb) Arterial calcification, generalized, of infancy, 2 614473 ABCC6 ATP‐BINDING CASSETTE, SUBFAMILY C, MEMBER 6 Pseudoxanthoma elasticum 264800 4,5 Pseudoxanthoma elasticum, forme fruste 177850 ACSL4 ACYL‐CoA SYNTHETASE LONG CHAIN FAMILY, MEMBER 4 Mental retardation, X‐linked 63 300387 2,1 AFF2 AF4/FMR2 FAMILY, MEMBER 2 (FMR2) Mental retardation, X‐linked, FRAXE type 309548 3,9 APOPTOSIS‐INDUCING FACTOR, MITOCHONDRION‐ASSOCIATED, 1 Combined oxidative phosphorylation deficiency 6 300816 AIFM1 1,8 (PDCD8) Cowchock syndrome 310490 Proteus syndrome, somatic 176920 AKT1 V‐AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 1 1,4 Cowden syndrome 6 615109 Megalencephaly‐polymicrogyria‐polydactyly‐hydrocephalus AKT3 V‐AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 3 (PKBG) 615937 1,4 syndrome 2 AP1S2 ADAPTOR‐RELATED PROTEIN COMPLEX 1, SIGMA‐2 SUBUNIT Mental retardation, X‐linked syndromic 5 304340 0,5 ARHGEF6 RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 6 (PIXA) Mental retardation, X‐linked 46 300436 2,3 ARHGEF9 RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 9 (PEM2) Epileptic encephalopathy, early infantile, 8 300607 1,6 ARID1A AT‐RICH INTERACTION DOMAIN‐CONTAINING PROTEIN 1A (SMARCF1) Coffin‐Siris syndrome 2 614607 6,9 ARID1B AT‐RICH INTERACTION DOMAIN‐CONTAINING PROTEIN 1B Coffin‐Siris syndrome 1 135900 6,7 Epileptic encephalopathy, early infantile, 1 308350 Hydranencephaly with abnormal genitalia 300215 Lissencephaly, X‐linked 2 300215 ARX ARISTALESS‐RELATED HOMEOBOX, X‐LINKED 1,7 Mental retardation, X‐linked 29 and others
    [Show full text]
  • Prenatal Microarray Disorders List V19.1
    Prenatal Microarray Disorders List v19.1 This "whole genome" array may identify genetic conditions not included in this list. If there is a family history of a known suspected genetic condition unrelated to the reason for testing, please contact the laboratory to discuss prior to sample submission. Chromosome Disorder / Syndrome OMIM Candidate Gene(s) Position 1p36 deletion syndrome 607872 1p36 Multiple 1q21.1 deletion syndrome, 1.35 Mb 612474 1q21.1-q21.2 Multiple 1q21.1 deletion with susceptibility to TAR 274000 1q21.1-q21.2 Multiple 1q21.1 duplication syndrome 612475 1q21.1-q21.2 Multiple 1q41-q42 deletion syndrome 612530 1q41-q42.12 Multiple 1q43-q44 deletion syndrome 612337 1q43-q44 AKT3, ZBTB18 2p16.1-p15 deletion syndrome 612513 2p16.1-p15 Multiple 2p21 microdeletion, homozygous 606407 2p21 Multiple 2q23.1 deletion syndrome 156200 2q23.1 MBD5 2q32-q33 deletion syndrome/ 2q33.1 deletion syndrome 612313 2q32-q33 SATB2 2q37 deletion syndrome 600430 2q37.3 HDAC4 3q13.31 deletion syndrome 615433 3q13.31 ZBTB20 3q26.33-3q27.2 deletion syndrome -- 3q26.33-3q27.2 Multiple 3q27.3 deletion syndrome -- 3q27.3 Multiple 3q29 deletion syndrome 609425 3q29 Multiple 4q21 deletion syndrome 613509 4q21 Multiple 5q14.3 deletion syndrome 613443 5q14.3 MEF2C 6pter-p24 deletion syndrome 612582 6pter-p24 Multiple 7q11.23 distal deletion syndrome 613729 7q11.23 Multiple 7q11.23 duplication syndrome 609757 7q11.23 Multiple 8p23.1 deletion/duplication syndrome 600576 8p23.1 GATA4 9q22.3 deletion syndrome 601309 9q22.3 PTCH1, FANCC 9q34.3 deletion syndrome
    [Show full text]
  • Neurological Syndromes
    Neurological Syndromes J. Gordon Millichap Neurological Syndromes A Clinical Guide to Symptoms and Diagnosis J. Gordon Millichap, MD., FRCP Professor Emeritus of Pediatrics and Neurology Northwestern University Feinberg School of Medicine Chicago, IL, USA Pediatric Neurologist Ann & Robert H. Lurie Children’s Hospital of Chicago Chicago , IL , USA ISBN 978-1-4614-7785-3 ISBN 978-1-4614-7786-0 (eBook) DOI 10.1007/978-1-4614-7786-0 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2013943276 © Springer Science+Business Media New York 2013 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc.
    [Show full text]
  • Utviklingsavvik V02
    2/1/2021 Utviklingsavvik v02 Avdeling for medisinsk genetikk Utviklingsavvik Genpanel, versjon v02 * Enkelte genomiske regioner har lav eller ingen sekvensdekning ved eksomsekvensering. Dette skyldes at de har stor likhet med andre områder i genomet, slik at spesifikk gjenkjennelse av disse områdene og påvisning av varianter i disse områdene, blir vanskelig og upålitelig. Disse genetiske regionene har vi identifisert ved å benytte USCS segmental duplication hvor områder større enn 1 kb og ≥90% likhet med andre regioner i genomet, gjenkjennes (https://genome.ucsc.edu). For noen gener ligger alle ekson i områder med segmentale duplikasjoner: ACTB, ACTG1, ASNS, ATAD3A, CA5A, CFC1, CLCNKB, CYCS, DDX11, GBA, GJA1, MSTO1, PIGC, RBM8A, RPL15, SBDS, SDHA, SHOX, SLC6A8 Vi gjør oppmerksom på at ved identifiseringav ekson oppstrøms for startkodon kan eksonnummereringen endres uten at transkript ID endres. Avdelingens websider har en full oversikt over områder som er affisert av segmentale duplikasjoner. ** Transkriptets kodende ekson. Ekson Gen Gen affisert (HGNC (HGNC Transkript Ekson** Fenotype av symbol) ID) segdup* AAAS 13666 NM_015665.6 1-16 Achalasia-addisonianism-alacrimia syndrome, 231550 AARS 20 NM_001605.2 2-21 Epileptic encephalopathy, early infantile, 29 616339 AARS2 21022 NM_020745.4 1-22 Combined oxidative phosphorylation deficiency 8, 614096 AASS 17366 NM_005763.4 2-24 Hyperlysinaemia (Disorders of histidine, tryptophan or lysine metabolism) ABAT 23 NM_020686.6 2-16 GABA transaminase deficiency (Disorders of neurotransmitter metabolism, gamma-aminobutyrate)
    [Show full text]
  • Charles Edward Schwartz JC Self Research
    NAME: Charles Edward Schwartz ADDRESS: (Office): JC Self Research Institute Greenwood Genetic Center 113 Gregor Mendel Circle Greenwood, SC 29646 Colgate University (Hamilton, NY) EDUCATION: Major - Chemistry B.A. - 1970 Oklahoma State University (Stillwater, OK) Major - Biochemistry M.S. - 1972 Vanderbilt University (Nashville, TN) Major - Biochemistry Ph.D. - 1978 POSITIONS: Research Assistant Long Island Jewish Hospital Hillside Medical Center New Hyde Park, New York 1972-1974 NCI Postdoctoral Fellow University of Vermont Department of Biochemistry Burlington, Vermont 1978-1980 Research Scientist La Jolla Cancer Research Foundation La Jolla, California 1980-1981 NIH Postdoctoral Fellow Division of Hematology/Oncology University of Utah School of Medicine Salt Lake City, Utah 1981-1983 Research Associate Department of Human Genetics University of Utah School of Medicine Salt Lake City, Utah 1983-1985 Director, Molecular Genetics Laboratory Greenwood Genetic Center Greenwood, SC 29646 July, 1985-December 1995 1 Last Updated on 02/08/16 at 10:42 AM Adjunct Associate Professor of Biological Sciences Clemson University Clemson, SC 1987-present Assistant Professor of Pediatrics University of South Carolina Columbia, SC 1987-present Adjunct Assistant Professor of Biology University of South Carolina Columbia, SC 1988-present Director, Center for Molecular Studies J.C. Self Research Institute Greenwood Genetic Center Greenwood, South Carolina 29646 January 1996-present Adjunct Professor, Department of Genetics and Biochemistry Clemson University
    [Show full text]
  • Hereditary Spastic Paraplegia Precision Panel Overview
    Hereditary Spastic Paraplegia Precision Panel Overview Hereditary Spastic Paraplegia (HSP) includes a group of familial diseases that are characterized by progressive degeneration of the corticospinal tracts responsible for movement and sensation. HSPs are differentiated into “pure” forms if there is bladder involvement and “complicated” if there are additional neurologic or systemic abnormalities. The genetic classification of HSP is based upon the mode of inheritance, chromosomal locus, and causative mutation. Modes of inheritance include autosomal dominant, autosomal recessive and X-linked forms. The correlation of clinical classification with genetic classification is not yet defined as some genetic types of HSP are associated with both pure and complex phenotypes. The Igenomix Hereditary Spastic Paraplegia Precision Panel can serve as an accurate and directed diagnostic tool as well as a differential diagnosis of muscle weakness ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. Indications The Igenomix Hereditary Spastic Paraplegia Precision Panel is indicated in patients with a clinical suspicion or diagnosis presenting with or without the following manifestations: ‐ Leg weakness ‐ Leg spasticity ‐ Brisk tendon reflexes ‐ Extensor plantar reflex ‐ Bladder dysfunction (urinary urgency) ‐ Visual loss ‐ Hearing loss ‐ Difficulty speaking ‐ Peripheral neuropathy Clinical Utility The clinical utility of this panel is: - The genetic and molecular diagnosis for an accurate clinical diagnosis of a symptomatic patient. 1 - Early initiation of treatment with a multidisciplinary team for symptomatic treatment to improve mobility, increase range of motion and relieve discomfort using pharmacologic treatment as well as physical medicine and rehabilitation.
    [Show full text]